ArticleJournal of thoracic disease2026
Risk factors associated with plastic bronchitis in children with severe
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development and validation of a nomogram for predicting recurrent plastic bronchitis in children with Mycoplasma pneumoniae pneumonia.Frontiers in pediatrics · 2026Article
- Lung ultrasound radiomics for identifying severeFrontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Plastic bronchitis (PB) represents a severe complication of Methods: A systematic literature search was conducted across PubMed/MEDLINE, Embase, Web of Science, Scopus, and Cochrane Library (January 1, 2015, to December 1, 2025). Case-control and cohort studies reporting risk factors for bronchoscopically confirmed PB in pediatric SMPP or RMPP patients were included. Methodological quality was assessed using the Newcastle-Ottawa Scale (NOS). Random-effects meta-analysis was performed using the DerSimonian-Laird method with Hartung-Knapp adjustment. Effect sizes were expressed as odds ratios (ORs) with 95% confidence intervals (CIs). Heterogeneity was quantified using I Results: Twelve studies (8 retrospective cohort, 2 case-control, 1 prospective cohort, 1 cohort with external validation; NOS range: 6-8) comprising 4,406 children (1,123 PB cases) were included, all originating from China. A total of 38 effect sizes across 8 risk factor categories were extracted; all were multivariate-adjusted ORs. Risk factors significantly associated with PB included: lactate dehydrogenase (LDH) elevation (k=4, OR =4.06, 95% CI: 2.69-6.11, P=0.002), prolonged fever duration (k=4, OR =3.70, 95% CI: 1.12-12.26, P=0.040), D-dimer elevation (k=3, OR =2.63, 95% CI: 2.01-3.43, P=0.004), pleural effusion (k=4, OR =2.46, 95% CI: 1.55-3.91, P=0.009), atelectasis (k=4, OR =2.32, 95% CI: 1.61-3.34, P=0.005), and consolidation involving ≥2/3 lung lobe (k=2, OR =1.79, 95% CI: 1.36-2.37, P=0.02). Radiological risk factors and LDH demonstrated consistently low heterogeneity (I Conclusions: Elevated LDH, prolonged fever duration, D-dimer elevation, and specific radiological features (pleural effusion, atelectasis, consolidation) are significantly associated with increased risk of PB in pediatric SMPP. These risk factors may inform early clinical risk stratification and guide decision-making regarding bronchoscopic intervention. However, their predictive accuracy requires formal evaluation using discrimination metrics. Future prospective multicenter studies are warranted to develop and validate clinical prediction models incorporating these factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.